Blue Cap AG, a Munich-based investment company, announced a significant change to its management board on October 6, 2026. Dr. Henning von Kottwitz, Chairman of the Management Board, will leave the company effective October 8, 2026, by mutual agreement with the Supervisory Board. The Supervisory Board has resolved to second its own Chairman, Dr. Christian Diekmann, to the Management Board as a full member starting October 9, 2026, under Section 105(2) of the German Stock Corporation Act. Dr. Diekmann will assume responsibility for strategy and finance, while Henning Eschweiler remains COO and will additionally take on M&A responsibilities.
This leadership transition is more than a routine succession; it signals a deepening of Blue Cap’s commitment to its Buy-Transform-Sell strategy amid a challenging economic environment. Dr. Diekmann, who has chaired the Supervisory Board since 2024, brings extensive experience in operational restructuring and managing medium-sized corporate groups, having served as CEO of Max Automation SE and CFO of the Zertus Group. His move to the Management Board ensures continuity and hands-on leadership at a time when many fundamentally sound companies face structural disruptions. As Dr. Michael Schieble, Deputy Chairman of the Supervisory Board, noted, Dr. Diekmann’s in-depth knowledge of Blue Cap positions him to “drive the further development of Blue Cap AG’s business model as a member of the Management Board in the near term and take it to the next level.”
Dr. Diekmann himself emphasized the opportunity: “Blue Cap AG is ideally positioned as an investor in ‘special situations’ to grow in the current economic environment. Many companies that are fundamentally well positioned for the future are increasingly affected by disruptions in industry and structural challenges. We aim to address these challenges through our business model, strengthen Germany as an industrial location and create value for our shareholders.” His appointment underscores Blue Cap’s focus on operational value creation and its role as a consolidator in the DACH region.
Blue Cap AG acquires medium-sized B2B companies in special situations, typically with revenues between EUR 20 million and EUR 200 million, and supports their development before selling them at a profit. The company currently holds majority stakes in six portfolio companies operating in plastics engineering, production engineering, pre-press solutions, life sciences, and business services, employing around 2,000 people across Germany, Europe, North America, and Asia. The shares are traded on the Open Market (Scale, Frankfurt, and m:access, Munich; ISIN: DE000A0JM2M1).
The transition comes at a critical juncture for Germany’s industrial landscape, where structural challenges and disruptions are increasingly affecting even well-positioned companies. By elevating Dr. Diekmann to the Management Board, Blue Cap aims to leverage his restructuring expertise to navigate these headwinds and create value for shareholders. The move also ensures that the Supervisory Board’s strategic oversight is directly integrated into day-to-day management, potentially accelerating decision-making and execution. As the company continues to pursue its Buy-Transform-Sell strategy, this leadership change could enhance its ability to identify and transform special situation investments. For more details, see the original release on www.newmediawire.com. Additional information is available at www.blue-cap.de.
